
Andrew Lai MS2  
*USF MCOM- LVHN Campus, Andrew.Lai@lvhn.org*

Patrick Philpot DO  
*Lehigh Valley Health Network, Patrick.Philpot@lvhn.org*

Jennifer Boucher PharmD  
*Lehigh Valley Health Network, Jenny.Boucher@lvhn.org*

Andrew Meyer MD  
*Lehigh Valley Health Network, andrew_s.meyer@lvhn.org*

Follow this and additional works at: [https://scholarlyworks.lvhn.org/select-program](https://scholarlyworks.lvhn.org/select-program)

Part of the [Medical Education Commons](https://scholarlyworks.lvhn.org/medical-education-commons)

Published In/Presented At  
An Outpatient Methadone Weaning Protocol by a Neonatal Intensive Care Unit for Neonatal Abstinence Syndrome

Andrew Lai, MPH1, Patrick Philpot, DO2, Jennifer Boucher, JD, PharmD2, Andrew Meyer, MD, MBA1,3
University of South Florida Morsani College of Medicine, Tampa, FL1
Division of Neonatology2, Department of Pediatrics2, Lehigh Valley Health Network, Allentown, PA

Introduction:
- Neonatal Abstinence Syndrome (NAS): neonatal withdrawal symptoms as a result of perinatal exposure to drugs, especially opiates, during pregnancy.
- The rate of NAS has increased by 300% in the United States since the 1980’s1.
- NAS treatment costs reach as high as $112.6 million dollars per year, the majority of which was heavily influenced by extended hospital stays2.
- Inpatient management using traditional strategies of care has led to a length of stay (LOS) range of 8-10 days with a median of 25-34 days3,4.
- Oei et al 20015 found that inpatient LOS was decreased with the establishment of an outpatient clinic designed specifically for managing NAS patients.
- The Neonatal Intensive Care Unit (NICU) at Lehigh Valley Health Network (LVHN) has adopted an outpatient methadone weaning protocol to treat NAS patients with the goal of limiting readmissions and decreasing inpatient length of stay.

Plan:
- Characterize patients with NAS, describe the current practices used at LVHN to treat infants with NAS, assess outcome variables at LVHN.

Do:
- All term newborns (>37 weeks Estimated Gestational Age) at Lehigh Valley Hospital - Cedar Crest (LVH-CC) between 1/1/2010 and 12/31/2014, admitted to LVH-CC, with an ICD-9 co-diagnosis of NAS at discharge were examined.
- Data collected via electronic medical records independently by at least two investigators.
- Exclusion criteria: treatment for NAS with medications other than opioids, an EGA less than 37 weeks at birth, congenital anomalies, iatrogenic NAS due to opiate administration while in the NICU, or infants of multiple gestation.

Study / Results:
- Figure 1: Inpatient Methadone Weaning Protocol. For infants with Fenneigos Scores ≥8, additional steps are taken such as supplementation with high-calorie formula and heat and hydrotherapy.
- Figure 2: Patient Characteristics. (A) Patient sex. There were no African-American patients. (C) Primary payer. (D) Oral fluids received.
- Figure 3: Common Co-Diagnoses. Most diagnoses were not given to more than one patient.
- Figure 4: Commonly Prescribed Medication. Morphone p.n.w. was prescribed in 71.43% of the patients.

Act / Conclusions:
- The establishment of a clear management protocol for infants discharged from the NICU for NAS has many advantages. It has been shown to increase opportunities for maternal-infant pair bonding due to shorter hospital stays and increased rates of breastfeeding6.
- Abdel-Latif et al. 20022 found that the role of breastfeeding in the outpatient management of NAS led to reduced withdrawal severity, delayed onset of NAS, and decreased need for pharmacotherapy.
- Backes et al. 20122 calculated that patients in combined inpatient-outpatient management plan saved on average $13,817 in hospital costs per patient compared to a traditional, inpatient-only management strategy.
- Next Steps: develop clinical pathway, consider cost savings.

Table 1: Secondary Patient Outcomes. There were 56 patients identified that met inclusion/exclusion criteria.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Median</th>
<th>Mean</th>
<th>SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Estimated Gestational Age</td>
<td>39.50</td>
<td>39.46</td>
<td>1.14</td>
</tr>
<tr>
<td>(Weeks)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Hospital Length of Stay (days)</td>
<td>10.00</td>
<td>12.21</td>
<td>5.32</td>
</tr>
<tr>
<td>Total Days on Methadone Treatment Before Discharge</td>
<td>8</td>
<td>10.05</td>
<td>5.11</td>
</tr>
<tr>
<td>Time to Q24 Methadone Dosing</td>
<td>5.93</td>
<td>7.45</td>
<td>4.02</td>
</tr>
<tr>
<td>Total Hospital Charges</td>
<td>$53,081.0</td>
<td>$61,421.66</td>
<td>$32,816.05</td>
</tr>
</tbody>
</table>

Literature cited:

Acknowledgments:
We would like to thank Claire Kukiela, MS, CPHQ, Clinical Quality Specialist, for her assistance in the data inquiry.